SCHEMBL16732832

SCHEMBL16732832

CC(C)(C)OC(=O)N1CC[C@H](C2CCC(=O)CC2)[C@@H]1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.39
GPR119 Q8TDV5 3/20 0.37
PREP P48147 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
NR1I2 O75469 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16733164 1.00 HSD17B10 (0.39) HSD17B10GPR119PREPSMN1; SMN2KDM4E
SCHEMBL25178930 0.90 GPR119 (0.40) HSD17B10GPR119PREPSMN1; SMN2
SCHEMBL16943559 0.87 NR1H2 (0.34) HSD17B10GPR119PREPDDB1CRBN
SCHEMBL16943563 0.87 NR1H2 (0.34) HSD17B10GPR119PREPDDB1CRBN
SCHEMBL5204649 0.85 HSD17B10 (0.44) HSD17B10GPR119PREPSMN1; SMN2
SCHEMBL5204656 0.85 HSD17B10 (0.44) HSD17B10GPR119PREPSMN1; SMN2
SCHEMBL15185120 0.85 HSD17B10 (0.44) HSD17B10GPR119PREPSMN1; SMN2
SCHEMBL5204643 0.85 HSD17B10 (0.44) HSD17B10GPR119PREPSMN1; SMN2
SCHEMBL16732850 0.85 HSD17B10 (0.44) HSD17B10GPR119PREPSMN1; SMN2
SCHEMBL16732847 0.85 HSD17B10 (0.44) HSD17B10GPR119PREPSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US disclosed
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US disclosed
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US disclosed
US-20150210640-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-07-30 US disclosed
US-20150210640-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-07-30 US disclosed
US-20150210640-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-07-30 US disclosed
EP-2876105-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2015-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210640-A1 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE RB1, F2, SFPQ HSD17B10 3097/4885GPR119 2564/4885PREP 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.